Literature DB >> 12524181

Developmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination.

Batool F Kirmani1, David M Jacobowitz, M A A Namboodiri.   

Abstract

Canavan disease, an autosomal-recessive neurogenetic disorder, is caused by mutations in aspartoacylase, an enzyme that deacetylates N-acetylaspartate to generate free acetate in the brain. Earlier studies have shown that aspartoacylase is primarily restricted to myelin synthesizing cells (oligodendroglia) in the CNS. These findings have led us to investigate the developmental expression of aspartoacylase gene in the rat brain in an attempt to shed more light on the role of this enzyme in myelination. In situ hybridization using a 35S riboprobe based on murine aspartoacylase cDNA was used in this study. The probe hybridized mostly to the white matter tracts with different densities depending on the age of the animal and region of the brain examined. Little or no hybridization signals were detected in the 1-day-old rats, whereas the signal was clearly detectable in most of the white matter regions of the CNS in the 11-day-old rats. The signal density markedly increased at postnatal day 17, the peak of myelination. Thereafter, the hybridization signals decreased somewhat but still could be observed in the adult animals. Thus, the developmental expression pattern of aspartoacylase gene in the postnatal brain closely parallels myelination in the CNS. In the CNS, the hybridization signal of ASPA appeared to be restricted primarily to oligodendrocytes, the primary myelin synthesizing cell type in the CNS. However, the signal was not detectable in rat sciatic nerve (Schwann cells) of the peripheral nervous system. These findings indicate that the role of N-acetylaspartate in myelin synthesis is restricted to the CNS. Furthermore, they provide additional support for the acetate deficiency hypothesis of Canavan disease and also make a stronger case for acetate supplementation as an immediate and inexpensive therapy for Canavan disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12524181     DOI: 10.1016/s0165-3806(02)00592-8

Source DB:  PubMed          Journal:  Brain Res Dev Brain Res        ISSN: 0165-3806


  21 in total

1.  Nuclear-cytoplasmic localization of acetyl coenzyme a synthetase-1 in the rat brain.

Authors:  Prasanth S Ariyannur; John R Moffett; Chikkathur N Madhavarao; Peethambaran Arun; Nisha Vishnu; David M Jacobowitz; William C Hallows; John M Denu; Aryan M A Namboodiri
Journal:  J Comp Neurol       Date:  2010-08-01       Impact factor: 3.215

2.  The impact of structural biology on neurobiology.

Authors:  Ronald E Viola
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

3.  Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease.

Authors:  Dominic J Gessler; Danning Li; Hongxia Xu; Qin Su; Julio Sanmiguel; Serafettin Tuncer; Constance Moore; Jean King; Reuben Matalon; Guangping Gao
Journal:  JCI Insight       Date:  2017-02-09

Review 4.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

5.  MR spectroscopy of the fetal brain: is it possible without sedation?

Authors:  V Berger-Kulemann; P C Brugger; D Pugash; M Krssak; M Weber; A Wielandner; D Prayer
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-19       Impact factor: 3.825

6.  Aspartoacylase supports oxidative energy metabolism during myelination.

Authors:  Jeremy S Francis; Louise Strande; Vladamir Markov; Paola Leone
Journal:  J Cereb Blood Flow Metab       Date:  2012-05-23       Impact factor: 6.200

7.  Transcriptional regulation of N-acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron-glia communication during energetic crisis.

Authors:  Samantha Zaroff; Paola Leone; Vladimir Markov; Jeremy S Francis
Journal:  Mol Cell Neurosci       Date:  2015-03-10       Impact factor: 4.314

8.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

9.  Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.

Authors:  Maria Traka; Robert L Wollmann; Sonia R Cerda; Jason Dugas; Ben A Barres; Brian Popko
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

Review 10.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.